JP2021506794A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506794A5
JP2021506794A5 JP2020532629A JP2020532629A JP2021506794A5 JP 2021506794 A5 JP2021506794 A5 JP 2021506794A5 JP 2020532629 A JP2020532629 A JP 2020532629A JP 2020532629 A JP2020532629 A JP 2020532629A JP 2021506794 A5 JP2021506794 A5 JP 2021506794A5
Authority
JP
Japan
Prior art keywords
seq
composition
peptide
nos
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/065545 external-priority patent/WO2019118779A2/en
Publication of JP2021506794A publication Critical patent/JP2021506794A/ja
Publication of JP2021506794A5 publication Critical patent/JP2021506794A5/ja
Priority to JP2023195583A priority Critical patent/JP2024026109A/ja
Pending legal-status Critical Current

Links

JP2020532629A 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 Pending JP2021506794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195583A JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598067P 2017-12-13 2017-12-13
US62/598,067 2017-12-13
PCT/US2018/065545 WO2019118779A2 (en) 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195583A Division JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Publications (2)

Publication Number Publication Date
JP2021506794A JP2021506794A (ja) 2021-02-22
JP2021506794A5 true JP2021506794A5 (https=) 2022-01-06

Family

ID=66820711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532629A Pending JP2021506794A (ja) 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Country Status (8)

Country Link
US (3) US11535649B2 (https=)
EP (1) EP3723781B1 (https=)
JP (2) JP2021506794A (https=)
CN (1) CN111712252A (https=)
AU (1) AU2018383669B2 (https=)
CA (1) CA3085576A1 (https=)
IL (1) IL275340A (https=)
WO (1) WO2019118779A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
BR112022006862A2 (pt) * 2019-10-10 2022-07-05 Univ New York State Res Found Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2025102083A1 (en) * 2023-11-12 2025-05-15 The Research Foundation For The State University Of New York Compositions and methods for treating pain or for increasing pain sensitivity
WO2025123001A1 (en) * 2023-12-08 2025-06-12 Washington University Targeted protein degradation compositions and methods of use thereof for pain control

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187533B1 (en) * 1996-09-10 2001-02-13 Arch Development Corporation Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α
SI2168984T1 (sl) * 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
EP1252330A2 (en) 1999-11-26 2002-10-30 McGill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US20030216310A1 (en) 2001-05-25 2003-11-20 Thornton Michael B. Transporters and ion channels
US20090087436A1 (en) 2001-07-13 2009-04-02 Myriad Genetics, Incorporated Compositions and methods for treating diseases
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1438584A4 (en) * 2001-10-01 2006-12-27 Buck Inst TARGET-ASSISTED ITERATIVE SCREENING (TAIS), NEW SCREEN FORMAT FOR LARGE MOLECULAR REPERTOIRES
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
WO2005059101A2 (en) 2003-12-12 2005-06-30 Wyeth Novel sodium channel
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005118614A1 (en) * 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
JP2010529966A (ja) 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてmiR−34によって調節される遺伝子および経路
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
JP2012503619A (ja) 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Hcv感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
EP2275545A1 (en) 2009-07-16 2011-01-19 Julius-Maximilians-Universität Würzburg Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
EP2478002B1 (en) * 2009-09-18 2015-02-25 University Of Houston Small peptide modulators of potassium channel trafficking
WO2012004664A2 (en) * 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
WO2012135666A1 (en) 2011-04-01 2012-10-04 University Of Louisiana At Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
EP2773366B1 (en) * 2011-11-04 2017-03-01 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP2019512015A (ja) * 2016-02-26 2019-05-09 ザ・ジョンズ・ホプキンス・ユニバーシティ 機械的刺激による痛みに関連する電位依存性ナトリウム・チャネルNav1.1に対する調節薬
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Similar Documents

Publication Publication Date Title
JP2021506794A5 (https=)
Park et al. Eosinophil survival and apoptosis in health and disease
Garden Epigenetics and the modulation of neuroinflammation
Fu et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis
Goldbach-Mansky Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1
JP2020519661A5 (https=)
Shi et al. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model
PY2089159A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
JP2024026109A5 (https=)
PY2157405A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
Zhang et al. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells
JP2019529541A5 (https=)
JP2011518168A5 (https=)
JP2011515357A5 (https=)
MX2022006214A (es) Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1.
Ververis et al. Potential non-oncological applications of histone deacetylase inhibitors
JP2024000505A5 (https=)
Deng et al. Interleukin-17 family in health and immune diseases: From origin to clinical implications
Clapier et al. Chromatin remodeling complexes
Katoch et al. HDAC inhibitors: applications in oncology and beyond
JP2011505798A5 (https=)
RU2018144784A (ru) Применение карбамата для предупреждения или лечения невралгии тройничного нерва
JP2019516722A5 (https=)
Srivastava et al. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics
Liang et al. Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications